NUTROPIN RECOMBINANT HUMAN GROWTH HORMONE IN POST RENAL TRANSPLANTATION

NUTROPIN 重组人类生长激素在肾移植后的应用

• 批准号: 6303441
• 负责人: JOSEPH T FLYNN
• 金额: $ 0.02万
• 依托单位: UNIVERSITY OF MICHIGAN AT ANN ARBOR
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-12-01 至 2001-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6303441
• 关键词: child (0-11); clinical research; drug adverse effect; hormone therapy; human subject; human therapy evaluation; kidney transplantation; pediatric pharmacology; postoperative state; recombinant proteins; somatotropin

Poor growth in children with renal failure (CRF) may not be corrected with renal transplantation. Recombinant human growth hormone (rhGH), now in use to treat children with CRF pre-transplantation, may be effective post-transplantation as well, but may cause unique problems such as chronic rejection. This study is intended to study the efficacy and safety of rhGH treatment in this population.

肾移植可能无法纠正肾衰竭（CRF）儿童的生长不良。重组人生长激素 (rhGH) 目前用于治疗移植前患有 CRF 的儿童，移植后也可能有效，但可能会导致慢性排斥等独特问题。本研究旨在研究 rhGH 治疗对该人群的有效性和安全性。